Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma

Abstract

Objectives To better define the relationship between platelet count and survival using a retrospective analysis in patients with thrombocytosis and metastatic renal cell carcinoma (RCC), some of whom had a shorter life expectancy than those with a normal platelet count. Patients and methods The records were reviewed of patients with stage IV RCC who had undergone a variety of adjuvant therapies after nephrectomy between 1972 and 1992. Entry criteria included a tissue diagnosis of RCC, at least one platelet count and a complete follow‐up until the time of death. Of 350 patients available for review, 259 met the entry criteria. Patients were divided into two groups: group 1 included 112 patients whose platelet counts remained at < 4 × 105/µL between the time of nephrectomy and the time of death; group 2 included 147 patients with at least one platelet count of > 4 × 105/µL (mean age in each group 57 years). Results The mean ( sd) survival for group 1 was 151 (34) months, compared with 92 (18) months for those in group 2. Using the log‐rank chi‐square test the difference in survival between the groups was significant (P = 0.005). Controlling for established prognostic indicators of pathological stage, nuclear grade and cell type, using Cox's regression technique, the difference in survival between the groups remained significant (P = 0.015). Conclusions These results suggest that patients with metastatic RCC who receive adjuvant therapy and have a persistently normal platelet count have a 64% longer life expectancy than those with thrombocytosis. The difference is highly statistically significant when controlled for nuclear grade, cell type and pathological stage.

The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment

“…However, its' prognostic importance have been observed frequently in patients with gynecological cancers, renal cell carcinoma, and lung cancer [21][22][23]. The prevalence of thrombocytosis in patients with gynecological cancer was 9.5-38%, 13-60% with primary lung cancer, 56.8% with renal cell carcinoma, and 33% with colon cancer [4,14,24,25]. We found that thrombocyte count was greater than 400.000/mm 3 in 13% of patients.…”

Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis

“…Similar identiWcation process was carried out in 127 studies for thrombocytosis and 74 studies for ESR. Finally, 15 studies for thrombocytosis (Bensalah et al 2006;Brookman-Amissah et al 2009;Cho et al 2008;Erdemir et al 2007;Gogus et al 2004;Ito et al 2006;Jacobsen et al 2002;Karakiewicz et al 2007;Lee et al 2006;Lehmann et al 2004;O'Keefe et al 2002;PXanz et al 2008;Ramsey et al 2008;Suppiah et al 2006;Symbas et al 2000) (Fig. 1B) and 14 studies for ESR were included (Fossa et al 1994;Kawai et al 2009;Lee et al 2006;Lehmann et al 2004;Ljungberg et al 1997;Magera et al 2008;Masuda et al 1997Masuda et al , 1998Miyata et al 2001;Roosen et al 1994;Sengupta et al 2006;Tanaka et al 2008;Tourani et al 2003;Zubac et al 2008) (Fig.…”

“…For CRP OS studies, the cut-oV value of CRP seemed to be a source of heterogeneity as heterogeneity did not exist in the group with CRP more than 8 mg/L. For PC OS studies, the extremely long follow-up duration in one study (Symbas 2000 study) may contribute to the heterogeneity. When we removed this special study, no heterogeneity was detected in the remaining studies.…”

Anemia and Elevated Systemic Levels of Vascular Endothelial Growth Factor (VEGF)

“…The storage of VEGF in and its release from platelets can be explained by the physiological role of VEGF during wound healing. In tumors, a correlation of high platelet counts with poor prognosis has been described in various cancers [11,15,30]. It is currently not clear whether this is only an epiphenomenon or whether platelets may play a specific role in angiogenesis in tumors.…”